HLB’s U.S. affiliate, Verismo Therapeutics and GC Cell’s U.S. affiliate, Artiva Biotherapeutics announced this week that they obtained phase 1 IND approval from the FDA for their respective next-generation chimeric antigen receptor (CAR-T) treatments.
 

Please refer to the following website for further details:   

Novel CAR-T therapies from HLB and GC Cell’s US affiliates take spotlight < Pharma < 기사본문 - KBR (koreabiomed.com)